Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Burkina Faso must 'forget' about democracy, military leader says - 2How to watch the 2025 Macy's Thanksgiving Day Parade for free
- 3A Past filled with Old Civilizations: The World's Most established Societies
- 4Exploring the School Application Cycle: Understudy Bits of knowledge
- 5Israel says it will keep control over part of southern Lebanon after war with Hezbollah ends
- Exploiting Unsold Rams: May Be Less expensive Than You Suspect
- Israel and Lebanon's Hezbollah continue to trade attacks
- 2023's Best 10 Cell phone Advancements You Can't Miss
- As world leaders enter climate talks, people in poverty have the most at stake
- Far-right leader Le Pen to attend Brigitte Bardot's funeral
- Kidneys from Black donors are more likely to be thrown away − a bioethicist explains why
- Palestinian infant freezes to death in Gaza as Israel keeps blocking aid
- Putting resources into Yourself: Self-awareness Techniques
- Picking the Right Home Machines: A Commonsense Aide
